Fulvestrant in postmenopausal women with locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy: a guide


    loading  Checking for direct PDF access through Ovid

Abstract

Fulvestrant (Faslodex®) is indicated for the treatment of postmenopausal women with advanced or metastatic breast cancer that has progressed on prior endocrine therapy. A regimen of fulvestrant 500 mg (i.e. 500 mg on days 0, 14 and 28, then 500 mg every 28 days) prolonged the time to disease progression and overall survival to a greater extent than a fulvestrant 250 mg regimen and was generally well tolerated in this patient population.

    loading  Loading Related Articles